With box warnings

Without box warnings

Branded

Generic

4 results

ambrisentan
(Ambrisentan)
Quallent Pharmaceuticals Health LLC
Usage: Ambrisentan tablets are indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical deterioration. It is primarily studied in patients with WHO Functional Class II–III symptoms, mainly due to idiopathic or heritable PAH or PAH linked to connective tissue diseases.
filspari
(sparsentan)
Travere Therapeutics, Inc.
Usage: FILSPARI is indicated for slowing the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
letairis
(AMBRISENTAN)
Gilead Sciences, Inc
Usage: Letairis is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening, and reduce disease progression and hospitalization risks when combined with tadalafil. It is primarily studied in patients with WHO Functional Class II–III symptoms related to idiopathic, heritable PAH, or connective tissue diseases.
opsumit
(macitentan)
Actelion Pharmaceuticals US, Inc.
Usage: OPSUMIT is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various forms of PAH, primarily those with WHO Functional Class II–III symptoms.

Endothelin Receptor Antagonist class drugs

ambrisentan